Skip to search formSkip to main contentSkip to account menu

SAR125844

Known as: MET Tyrosine Kinase Inhibitor SAR125844 
An inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Upon… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

BenzothiazolesUrea
Receptor Tyrosine Kinase Inhibitionanalogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results.
2506 Background: SAR125844 (SAR) is a potent and highly selective MET kinase inhibitor (IC50= 4.2 nM; Ki = 2.8 nM) demonstrated… 
2012
2012
Abstract 2911: SAR125844: a potent and selective ATP-competitive inhibitor of MET kinase
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL The tyrosine kinase MET is a membrane receptor… 
2012
2012
Abstract 845:In vitroandin vivopharmacology of SAR125844, a potent and selective intravenous MET kinase inhibitor undergoing Phase I clinical trial
SAR125844 is a potent MET kinase inhibitor for intravenous (IV) administration, with nanomolar activity against the wild-type… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)